Seilern Investment Management Ltd Sells 10,499 Shares of Edwards Lifesciences Corporation $EW

Seilern Investment Management Ltd decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 589,732 shares of the medical research company’s stock after selling 10,499 shares during the period. Edwards Lifesciences accounts for about 6.4% of Seilern Investment Management Ltd’s holdings, making the stock its 5th largest holding. Seilern Investment Management Ltd’s holdings in Edwards Lifesciences were worth $50,906,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. Bank of America Corp DE bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $605,397,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Edwards Lifesciences by 0.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after acquiring an additional 30,495 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $0.77 during midday trading on Tuesday, reaching $85.62. 964,470 shares of the company were exchanged, compared to its average volume of 4,496,346. The stock has a market cap of $49.30 billion, a PE ratio of 49.24, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87. The business’s fifty day moving average is $88.67 and its two-hundred day moving average is $86.22. Edwards Lifesciences Corporation has a one year low of $72.40 and a one year high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. BTIG Research reissued a “buy” rating and set a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Barclays upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, October 7th. Finally, Evercore restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,428,912.10. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.